PPARA and metabolic dysfunction-associated steatohepatitis: In Alb/AEG-1 mice, PPARα inhibition leads to decreased FAO and increased Fas translation, driving DNL and activating NF-κB-mediated inflammation—together contributing to NASH pathology.